TG THERAPEUTICS INC. Company News: Berger Montague Investigating Allegations of Securities Fraud Against TG Therapeutics Inc. (NASDAQ: TGTX); The deadline for the main applicant is September 16, 2022

PHILADELPHIA CREAM, August 4, 2022 /PRNewswire/ — Shepherd Montague is investigating allegations of securities fraud on behalf of investors who purchased TG Therapeutics Inc. (“TG” or the “Company”) (NASDAQ: TGTX) securities between January 15, 2020 and May 31, 2022 (the “Class Period”).

Investigating allegations of securities fraud on behalf of investors who purchased TG Therapeutics Inc.

If you purchased the TG Securities during the Class Period, would like to discuss At Berger Montague investigation, or if you have any questions regarding your rights or interests, please contact the lawyers Andre Abramowitz at [email protected] or (215) 875-3015, or Michael Dell‘Angelo at [email protected] or (215) 875-3080 or visit:

Whistleblowers: Anyone with non-public information about TG is encouraged to help confidentially. At Berger Montague survey or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

According to a recently filed lawsuit, the defendants made false and misleading statements regarding clinical trial data that raised significant concerns about the safety of Ublituximab and Umbralisib, making it unlikely that the FDA approves TG applications in their current forms.

Investors learned the truth through a series of partial disclosures beginning on November 30, 2021when TG announced that the FDA planned to hold an oncology drug advisory committee meeting as part of its review of TG’s clinical trials for Ublituximab and Umbralisib.

On April 15, 2022, TG announced the withdrawal of its New Drug Application and Biologics License Application based on safety data. Then, on June 1, 2022the FDA announced that it was revoking the approval of Umbralisib for the treatment of certain indications due to safety concerns.

Shepherd Montaguewith offices at philadelphia cream, Minneapolis, washington d.c.and San Diegohas been a pioneer in securities class actions since its founding in 1970. Shepherd Montague has represented individual and institutional investors for over five decades and acts as lead counsel before courts across United States.

Andre Abramowitzsenior counsel
Shepherd Montague
(215) 875-3015
[email protected]

Michael Dell‘Angelo, executive shareholder
Shepherd Montague
(215) 875-3080
[email protected]


Show original content to download multimedia: the-applicant-deadline-is-16-September-2022-301600351.html

THE SOURCE Shepherd Montague

Karen J. Nelson